ClinicalTrials.gg
TerminatedNCT05636176HERMESUpdated Oct 1, 2026

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

A Phase 3 interventional study of Ziltivekimab and Placebo in Heart Failure, sponsored by Novo Nordisk A/S. Terminated at 1,013 sites in 46 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Why this study was terminated
No longer looking for participants.
Updated Oct 1, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,874
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Heart Failure by Novo Nordisk A/S — 5 open to participants now, 6 under way, 2 of them phase 3. Heart Failure · Novo Nordisk A/S.

Enrollment
2nd of 11
4,874 · median 200
Started
2023
with 1 other
Phase 3
3 of 14
1 open now
Registered
3rd of 14
by date

Among the 14 studies in Heart Failure by Novo Nordisk A/S, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 3, and was the 3rd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum high-sensitivity C-reactive protein (hs-CRP) greater than equal to 2 milligrams per liter (mg/L) at screening (visit 1) Disease specific - cardiovascular
  • At least one of the following:

    1. N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than equal to 300 picograms per milliliter (pg/mL) at screening (Visit 1) for patients without ongoing atrial fibrillation/flutter. If ongoing atrial fibrillation/flutter at screening (visit 1), NTproBNP must be greater than equal to 600 pg/mL. Note that the screening (ECG) must be obtained the same day as sampling for NT-proBNP.
    2. Hospitalisation or urgent/unplanned visit with a primary diagnosis of decompensated heart failure which required intravenous loop diuretic treatment, within the last 9 months prior to screening (visit 1) in combination with NT-proBNP greater than equal to 200 pg/mL at screening (Visit 1) for patients without ongoing atrial fibrillation/flutter. If ongoing atrial fibrillation/flutter at screening (visit 1), NT-proBNP must be greater than equal to 600 pg/mL.
  • Diagnosis of heart failure ( [classification] [NYHA] Class II-IV).
  • (LVEF) greater than 40 percentage (%) documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (e.g., myocardial infarction [MI] or heart failure [HF] hospitalisation).
  • Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following:
  • Left atrial (LA) volume index greater than 34 milliliters per meter square (mL/m\^2).
  • LA diameter greater than equal to 3.8 centimeters (cm).
  • LA length greater than equal to 5.0 cm.
  • LA area greater than equal to 20 cm square.
  • LA volume greater than equal to 55 milliliters (mL).
  • Intraventricular septal thickness greater than equal to 1.1 cm.
  • Posterior wall thickness greater than equal to 1.1 cm.
  • Left ventricular (LV) mass index greater than equal to 115 grams per meter square (g⁄m\^2 ) in men or greater than equal to 95 g⁄m\^2 in women.
  • E/e' (mean septal and lateral) greater than equal to 10.
  • e' (mean septal and lateral) less than 9 centimeter per second (cm/s).
  • No heart failure hospitalisations or urgent heart failure visits between screening (visit 1) and randomisation (visit 2).

Exclusion criteria

Exclusion Criteria:

Medical conditions - cardiovascular

  • Myocardial infarction, stroke, unstable angina pectoris, , or heart failure hospitalisation, within 30 days prior to screening (visit 1).
  • Systolic blood pressure greater than equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than equal to 3 antihypertensive drugs. (Note: Potential participants may be retested for this criterion within the visit window and without rescreening, at the discretion of the investigator).
  • Heart rate above 110 or below 40 beats per minute as evaluated on the (ECG) performed at screening (visit 1) (Note: Potential participants may be retested for this criterion within the visit window and without rescreening, at the discretion of the investigator).
  • Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1). (Note: Planned coronary angiogram is not exclusionary).
  • Planned cardiac device or atrial flutter/atrial fibrillation ablation procedure known during the screening period (visit 1).
  • Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2).
  • Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease.
  • Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including .
  • Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism).

Medical conditions - infections/

- Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,874 participants (actual)

Study arms

  • Experimental
    Ziltivekimab

    Participants will receive ziltivekimab subcutaneous (s.c.) injection once-monthly and added standard of care for up to 4 years.

    Drug: Ziltivekimab

  • Placebo comparator
    Placebo

    Participants will receive ziltivekimab placebo s.c. injection once-monthly and added standard of care for up to 4 years.

    Drug: Placebo

Interventions

  • Ziltivekimab subcutaneous (s.c.) injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.

  • DrugPlacebo

    Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of a Composite Heart Failure Endpoint Consisting of: Cardiovascular (CV) Death, Heart Failure (HF) Hospitalisation or Urgent HF Visit

    Measured in months.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

Secondary outcomes

  1. Time to First Occurrence of 4-point Expanded Composite HF Endpoint, a Composite Endpoint Consisting of: CV Death, HF Hospitalisation or Urgent HF Visit, Non-fatal Myocardial Infarction (MI), Non-fatal Stroke

    Measured in months.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  2. Number of CV Deaths, HF Hospitalisations or Urgent HF Visits (First and Recurrent)

    Measured as count of event.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  3. Time to Occurrence of CV Death

    Measured in months.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  4. Time to Occurrence of all-cause Death

    Measured in months.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  5. Time to First Occurrence of 4-point Expanded Composite HF Endpoint, a Composite Endpoint Consisting of: All-cause Death, HF Hospitalisation or Urgent HF Visit, Non-fatal MI, Non-fatal stroke

    Measured in months.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  6. Hierarchical Composite of: Time to All-cause Death, Number of HF Hospitalisations or Urgent HF Visits, Time to First HF Hospitalisation or Urgent HF Visit, difference of at least 5 in KCCQ clinical summary score change from baseline to 12 months

    Kansas City Cardiomyopathy Questionnaire (KCCQ) measures Health-Related Quality of Life (HRQOL) and is a disease-specific health status instrument for HF. Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms, and greater disease-specific health related quality of life, respectively. Measured as total wins for each treatment group.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  7. Time to First Occurrence of HF Hospitalisation or Urgent HF Visit

    Measured in months.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  8. Number of Events of Atrial Fibrillation

    Measured as count of event.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  9. Change in KCCQ Clinical Summary Score

    KCCQ measures Health-Related Quality of Life (HRQOL) and is a disease-specific health status instrument for HF. Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms, and greater disease-specific health related quality of life, respectively. Measured as score.

    Time frame: From randomisation (month 0) to 12 months

  10. Improvement of 5 Points or More in KCCQ Clinical Summary Score (Yes/No)

    Kansas City Cardiomyopathy Questionnaire (KCCQ) measures Health-Related Quality of Life (HRQOL) and is a disease-specific health status instrument for HF. Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms, and greater disease-specific health related quality of life, respectively. Measured as count of participant.

    Time frame: From randomisation (month 0) to 12 months

  11. Improvement of 10 Points or More in KCCQ Clinical Summary Score (Yes/No)

    Kansas City Cardiomyopathy Questionnaire (KCCQ) measures Health-Related Quality of Life (HRQOL) and is a disease-specific health status instrument for HF. Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms, and greater disease-specific health related quality of life, respectively. Measured as count of participant.

    Time frame: From randomisation (month 0) to 12 months

  12. Improvement in New York Heart Association (Classification) [NYHA Class] (Yes/No)

    NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Participant with cardiac disease but without resulting limitations of physical activity. Class II: Participants with cardiac disease resulting in slight limitation of physical activity. Class III: Participants with cardiac disease resulting in marked limitation of physical activity. Class IV: Participants with cardiac disease resulting in inability to carry on any physical activity without discomfort. Measured as count of participant.

    Time frame: From randomisation (month 0) to 12 months

  13. Time to First Occurrence of a Composite Chronic Kidney Disease (CKD) Endpoint Consisting of: CV death, Onset of Persistent Greater Than Equal To 40 Percentage Reduction in eGFR (CKD- EPI) compared with baseline; Kidney failure

    eGFR = estimated glomerular filtration rate; CKD-EPI = chronic kidney disease - epidemiology collaboration. Kidney failure defined as: death from kidney failure, onset of persistent eGFR less than 15 milliliters per minute (mL/min)/1.73 meter square (m\^2) (CKD-EPI), initiation of chronic kidney replacement therapy (maintenance dialysis or kidney transplantation). Measured in months.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  14. Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease - Epidemiology Collaboration [CKD-EPI])

    Measured as mL/min/1.73 m\^2.

    Time frame: From randomisation (month 0) to 12 months

  15. Annual Rate of Change in eGFR (CKD-EPI) (Total eGFR Slope)

    Measured as mL/min/1.73 m\^2/year.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  16. Number of Hospitalisations With Infection as Primary Cause or Death Due to Infection

    Measured as count of event.

    Time frame: From randomisation (month 0) to end of study (up to 48 months)

  17. Change in High-sensitivity C-reactive Protein (hs-CRP)

    Measured as ratio to baseline.

    Time frame: From randomisation (month 0) to 12 months

  18. Change in N-terminal-pro-brain Natriuretic Peptide (NT-proBNP)

    Measured as ratio to baseline.

    Time frame: From randomisation (month 0) to 12 months

07

Study locations

1,013 sites
  • Advanced Cardiovascular, LLC
    Alexander City, Alabama 35010, United States
  • Eastern Shore Rsrch Inst, LLC
    Fairhope, Alabama 36532, United States
  • Heart Center Rsrch_Hunstville
    Huntsville, Alabama 35801, United States
  • Banner University Medical Ctr
    Phoenix, Arizona 85006, United States
  • Cardiology & Medicine Clinic
    Little Rock, Arkansas 72204, United States
  • InvivoCure -2
    Alhambra, California 91801, United States
  • National Heart Institute Cal
    Beverly Hills, California 90211, United States
  • Valley Clinical Trials
    Covina, California 91723, United States
  • Scripps Memorial Hospital La Jolla
    La Jolla, California 90237, United States
  • Purushotham & Akther Kotha MD, inc.
    La Mesa, California 91942, United States
  • VA Loma Linda Hlthcr Sys
    Loma Linda, California 92357, United States
  • Biopharma Clinical Research Services, LLC
    Los Angeles, California 90035, United States
  • VA Greater Los Angeles Hlthcare System
    Los Angeles, California 90073, United States
  • VAGrtrLosAngelesHlthcareSystem
    Los Angeles, California 90073, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • UCI Health
    Orange, California 92868, United States
  • Stanford Univ School of Med
    Palo Alto, California 94304, United States
  • San Diego Cardiac Center
    San Diego, California 92123, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • Manshadi Heart Institute
    Stockton, California 95204, United States
  • Lundquist Inst-Biomed Innovtn
    Torrance, California 90502, United States
  • InvivoCure
    Van Nuys, California 91405, United States
  • Rocky Mountain Regional VAMC
    Aurora, Colorado 80045, United States
  • InvivoCure -2
    Denver, Colorado 80012, United States
  • S Denver Cardiology Associates
    Littleton, Colorado 80120, United States
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • Cardiology Associates of Fairfield County
    Stamford, Connecticut 06905, United States
  • Pioneer Clinical Studies-Coral Gables
    Coral Gables, Florida 33134, United States
  • Nature Coast Clin Rsrch_Crystal River
    Crystal River, Florida 34429, United States
  • Integrative Research Assoc Inc
    Fort Lauderdale, Florida 33312, United States
  • New Generation of Medical Research
    Hialeah, Florida 33016, United States
  • Memorial Region Hosp_Hollywood
    Hollywood, Florida 33021, United States
  • E Coast Inst for Rsrch LLC_Jacksonville
    Jacksonville, Florida 32204, United States
  • Jacksonville Ctr for Clin Res
    Jacksonville, Florida 32216, United States
  • Baptist Health Research Institute
    Jacksonville, Florida 32258, United States
  • Baptist Health South Florida
    Miami, Florida 33173, United States
  • Pioneer Clinical Studies-Coral Gables
    Miami, Florida 33176, United States
  • NCH Research Institute
    Naples, Florida 34102, United States
  • Amavita Research Services, LLC
    North Miami Beach, Florida 33169, United States
  • Ocala Cardiovascular Research
    Ocala, Florida 34471, United States
  • Ormond Beach Clinical Research
    Ormond Beach, Florida 32174, United States
  • St Johns Ctr Clin Rsch-St. Aug
    Saint Augustine, Florida 32086, United States
  • Cardio Partners Clin Res Inst
    Wellington, Florida 33449, United States
  • Winter Haven Hospital
    Winter Haven, Florida 33881, United States
  • Guardian Research Org LLC
    Winter Park, Florida 32792, United States
  • Morehouse School of Medicine
    Atlanta, Georgia 30310, United States
  • Emory University School of Medicine_Atlanta
    Atlanta, Georgia 30322, United States
  • NSC Research, Inc
    Johns Creek, Georgia 30024, United States
  • GA Arrhythmia Cons & Rsch Inst
    Macon, Georgia 31201, United States
  • The Queen's Medical Center
    Honolulu, Hawaii 96817, United States
  • St. Luke's Idaho Cardiology Associates
    Meridian, Idaho 83642, United States
  • Endeavor Health Clinical Operations-NCH
    Arlington Heights, Illinois 60005, United States
  • Advocate Good Samaritan
    Downers Grove, Illinois 60515, United States
  • Chicago Medical Research LLC
    Hazel Crest, Illinois 60429, United States
  • Midwest Cardiovascular Institute
    Naperville, Illinois 60540, United States
  • OSF HealthCare_Cardiovasc Inst
    Peoria, Illinois 61614, United States
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61636, United States
  • Midwest Cardiovascu Rsrch Foundation
    Elkhart, Indiana 46514, United States
  • Asha Clinical Rsch-Munster, LLC
    Hammond, Indiana 46324, United States
  • Franciscan Network-IN Heart PHY
    Indianapolis, Indiana 46237, United States
  • Witham Health Services
    Lebanon, Indiana 46052, United States
  • Cardiovascular Rsrch of NW_IN
    Munster, Indiana 46321, United States
  • Reid Physician Associates
    Richmond, Indiana 47374, United States
  • University Of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Midwest Heart & Vasc Spec
    Overland Park, Kansas 66211, United States
  • Baptist Health Hardin
    Elizabethtown, Kentucky 42701, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • University Of Louisville
    Louisville, Kentucky 40202, United States
  • Robley Rex VA Medical Center
    Louisville, Kentucky 40206, United States
  • Baptist Health Louisville
    Louisville, Kentucky 40207, United States
  • Cambridge Medical Trials
    Alexandria, Louisiana 71301, United States
  • LOUISIANA HEART Center
    Bogalusa, Louisiana 70427, United States
  • Heart Clinic of Hammond
    Hammond, Louisiana 70403, United States
  • University Medical Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Ascension Saint Agnes Heart Ca
    Baltimore, Maryland 21229, United States
  • Johns Hopkins University_Baltimore
    Baltimore, Maryland 21287, United States
  • Capitol Cardiology Assoc_Lanham
    Lanham, Maryland 20706, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Mass General Community Physicians
    Haverhill, Massachusetts 01830, United States
  • University of Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • Detroit Med Center-Wayne State
    Detroit, Michigan 48201, United States
  • Henry Ford Hlth System_Detroit
    Detroit, Michigan 48202, United States
  • Elite Research Center
    Flint, Michigan 48532, United States
  • Healthy Heart Cardiology
    Grand Rapids, Michigan 49546, United States
  • Trinity Health Michigan Heart
    Ypsilanti, Michigan 48197, United States
  • Fairview Health Services
    Maplewood, Minnesota 55109, United States
  • Minneapolis VA Health Care Sys
    Minneapolis, Minnesota 55417, United States
  • Hawthorne Health
    Diamondhead, Mississippi 39525, United States
  • Cardiolg Assoc Rsch LLC_Tupelo
    Tupelo, Mississippi 38801, United States
  • St Louis Heart & Vascular, P.C.
    St Louis, Missouri 63136, United States
  • Logan Health Research
    Kalispell, Montana 59901, United States
  • Univ. of Nebraska Medical Center_Omaha
    Omaha, Nebraska 68198, United States
  • Palm Research Center Inc.
    Las Vegas, Nevada 89128, United States
  • Advanced Heart Care LLC
    Bridgewater, New Jersey 08807-3064, United States
  • Heart House_Elmer
    Elmer, New Jersey 08318, United States
  • NJ Heart
    Linden, New Jersey 07036, United States
  • Barnabas Health
    Livingston, New Jersey 07039, United States
  • Inspira Health - Cardiology
    Mullica Hill, New Jersey 08062, United States
  • Saint Michael's Med Ctr NJ
    Newark, New Jersey 07102, United States
  • The Valley Hosptial - Ridgewood
    Ridgewood, New Jersey 07450, United States

Showing the first 100 of 1,013 sites across 46 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Sep 2026, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Dec 5, 2022
StartActual
May 8, 2023
Primary completionActual
Sep 3, 2026
CompletionActual
Sep 3, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
4899→4874
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Enrollment 4899→4874

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05636176
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 5, 2022
Start date
May 8, 2023
Primary completion
Sep 3, 2026
Completion
Sep 3, 2026
Last update
Oct 1, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion